Humira, Abbott Laboratories' injectable drug, has obtained FDA clearance to treat moderate-to-severe juvenile idiopathic arthritis in patients aged 4 years and older. The drug, which is administered every two weeks, is the first biological treatment for the disease to obtain approval since 1999, Abbot said. Humira is already approved for the treatment of rheumatoid arthritis and other conditions in adults.

Full Story:

Related Summaries